Proton Partners International Ltd, the company building a £35 million cancer centre in Liverpool, is set to outline why the North West is leading the way in the bringing the latest cancer treatment and research to the region.
Led by Liverpool-born CEO Mike Moran, the company has successfully received formal planning permission to build an oncology centre in Liverpool, known as The Rutherford Cancer Centre North West. The centre will be part of the new £1 billion Knowledge Quarter (KQ) in Paddington Village.
Proton Partners International is also developing a genomics research centre in the city’s Life Sciences Accelerator building. The programme will be the first part of a health campus set to surround the £335m new Royal Liverpool Hospital.
Ad Statistics
Times Displayed: 50697
Times Visited: 1465 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Additionally, Proton Partners International has also agreed to a two-year collaborative research project with The University of Liverpool to develop a new measurement system, known as a 3D Water Phantom, to enhance proton beam therapy technology.
The company, which is also building centres in Newport, Northumberland and Reading, will share its plans for the region at the NCRI Cancer Conference, taking place at the BT Convention Centre this week.
The Rutherford Cancer Centre North West will bring the most advanced treatments in cancer care to the North West, including high-energy proton beam therapy (a treatment not currently available in the UK), as well as the latest technology on the market to deliver radiotherapy, chemotherapy, imaging and diagnostics. The conventional treatments will be available from 2018 and high-energy proton beam therapy will be available from 2019.
The Rutherford Cancer Centre North West will treat up to 500 patients a year and treatment will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.
Mike Moran, CEO of Proton Partners International, said: “We are proud to showcase our plans for Liverpool and the UK at this year’s NCRI Cancer Conference.
“Our mission is to make the best cancer care accessible to patients across the country and being from Liverpool myself, I’m incredibly proud that my city is not only leading the way in advancing treatment provision, but it is also at the forefront of world-leading research projects.”
The company’s first centre in Newport, The Rutherford Cancer Centre South Wales, recently opened to treat patients with chemotherapy and radiotherapy, and the high energy proton beam therapy system is currently undergoing installation.
The NCRI Cancer Conference, taking place at the BT Convention Centre from 5th-8thNovember, will attract over 1,500 delegates each year and provides a platform for researchers, clinicians and industry representatives to together to discuss, present and showcase high-quality research.
